Conar Fitton, MD
Gastroenterology · Kenner, LANPI 1316182744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $815,017 of the $954,680 with a category attached, or 85.4%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 63.6% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $296,605, 2.5 times the $116,933 reported in 2019. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,065 payments — averaging $896.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$607K
- Sanofi$150K
- Novo Nordisk$78K
- Phathom Pharmaceuticals, Inc.$64K
- Ipsen Biopharmaceuticals, Inc$24K
- AbbVie$23K
- plus $9K from 11 others
Across 61 payments — averaging $11,152 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$368K
- Braintree Laboratories, Inc.$285K
- AbbVie$23K
- Bausch Health US, LLC$5K
What the payments were for
- Consulting fees$11,3601%
- Speaking & faculty fees$815,01785%
- Travel & lodging$104,60811%
- Food & beverage$23,6182%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 723 | $606,939 |
| Sanofi | 90 | $149,694 |
| Novo Nordisk | 51 | $78,362 |
| Phathom Pharmaceuticals, Inc. | 84 | $63,948 |
| Ipsen Biopharmaceuticals, Inc | 18 | $23,571 |
| AbbVie(2 entities) | 58 | $22,990 |
| Regeneron Healthcare Solutions, Inc. | 12 | $8,258 |
| Redhill Biopharma Inc. | 9 | $176 |
| Medtronic | 2 | $166 |
| Covidien LP | 2 | $154 |
| Exact Sciences | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $117 |
| Johnson & Johnson | 1 | $93 |
| Ironwood Pharmaceuticals, Inc | 4 | $54 |
| Boston Scientific | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
| KCI USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$954,680 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 50 | $1,317,925 |
| Humira PenAdalimumab | 74 | $616,359 |
| Humira(Cf)Adalimumab | 13 | $338,378 |
| XifaxanRifaximin | 29 | $88,544 |
| LinzessLinaclotide | 14 | $14,350 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 107 | $6,301 |
| Pantoprazole Sodium | 49 | $568 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 13 | $513 |
| Azathioprine | 14 | $226 |
| Omeprazole | 13 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $93 | $1,317,92550 claims |
| AbbVieHumira(Cf), Linzess | $22,990 | $352,72827 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $606,939 | $88,54429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Kenner
- Daniel RainesKenner$37K
- Jonathon ChapmanBaton Rouge$998K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Shamita ShahNew Orleans$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.